Monopar Therapeutics Inc. (MNPR)

Monopar Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	7.27	8.19	20.3	16.74	13.21
Short-Term Investments	0	4.93	0	0	0
Cash & Cash Equivalents	7.27	13.12	20.3	16.74	13.21
Cash Growth	-44.62%	-35.38%	21.31%	26.66%	91.71%
Other Current Assets	0.07	0.05	0.22	0.06	0.02
Total Current Assets	7.33	13.17	20.52	16.8	13.23
Property, Plant & Equipment	0.01	0.06	0	0	0
Other Long-Term Assets	0	0	0	0.07	0.12
Total Long-Term Assets	0.01	0.06	0	0.07	0.12
Total Assets	7.35	13.23	20.52	16.87	13.35
Accounts Payable	1.76	3.13	1.58	1.18	0.72
Total Current Liabilities	1.76	3.13	1.58	1.18	0.72
Long-Term Debt	0	0.01	0	0	0
Total Long-Term Liabilities	0	0.01	0	0	0
Total Liabilities	1.76	3.14	1.58	1.18	0.72
Total Debt	0	0.01	0	0	0
Retained Earnings	-60.21	-51.8	-41.29	-32.19	-25.88
Comprehensive Income	-0.01	0.01	-0	-0.01	-0.01
Shareholders' Equity	5.59	10.09	18.94	15.69	12.63
Net Cash / Debt	7.27	13.11	20.3	16.74	13.21
Net Cash / Debt Growth	-44.58%	-35.42%	21.31%	26.66%	91.71%
Net Cash Per Share	0.53	1.03	1.63	1.53	1.42
Working Capital	5.58	10.04	18.94	15.62	12.51
Book Value Per Share	0.40	0.79	1.52	1.43	1.35

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).